<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982604</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-179</org_study_id>
    <nct_id>NCT01982604</nct_id>
  </id_info>
  <brief_title>Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Crossover Clinical Trial to Evaluate PK/PD of 30 U TI Inhalation Powders Prepared With Insulin From Two Different Suppliers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-label randomized crossover trial in Healthy Volunteers to evaluate the PK/PD&#xD;
      of TI (Technosphere® Insulin) prepared with insulin from two different suppliers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area-under-the-serum-insulin concentration time curve) 0 - 240 minutes</measure>
    <time_frame>5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 210, 240</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum serum insulin concentration)</measure>
    <time_frame>5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 210, 240</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIR (area-under-the-serum Glucose Infusion Rate)</measure>
    <time_frame>0 to 360</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence (Group) 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Sequence 1 will receive TI in the following sequence:&#xD;
TI-Inhalation Powder A TI-Inhalation Powder B&#xD;
*30 units (10 units + 20 units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence (Group) 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Sequence 2 will receive TI in the following sequence:&#xD;
TI-Inhalation Powder B TI-Inhalation Powder A&#xD;
*30 units (10 units + 20 units)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TI-Inhalation Powder A</intervention_name>
    <description>Inhaled Insulin</description>
    <arm_group_label>Sequence (Group) 1</arm_group_label>
    <arm_group_label>Sequence (Group) 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TI-Inhalation Powder B</intervention_name>
    <description>Inhaled Insulin</description>
    <arm_group_label>Sequence (Group) 1</arm_group_label>
    <arm_group_label>Sequence (Group) 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 to 55 years, considered healthy based on screening physical&#xD;
             examination, medical history, clinical chemistry, and urinalysis&#xD;
&#xD;
               -  HNVs with a screening blood pressure less than 140/90 mm Hg&#xD;
&#xD;
               -  Subjects who have hypertension controlled with up to 1 medication and who have a&#xD;
                  blood pressure less than 140/90 mm Hg&#xD;
&#xD;
               -  Note: For subjects with blood pressure at or above 140/90 mm Hg; two additional&#xD;
                  readings 5 minutes apart are allowed but the last blood pressure reading must be&#xD;
                  in range&#xD;
&#xD;
               -  Subjects who have hypercholesterolemia controlled with up to 1 medication and who&#xD;
                  have a low-density lipoprotein value less than 160 mg/dL&#xD;
&#xD;
          -  Good venous access for blood draws&#xD;
&#xD;
          -  No smoking in the past 6 months (including cigarettes, cigars, and pipes) and urine&#xD;
             cotinine testing &lt; 100 ng/mL&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 32 kg/m2&#xD;
&#xD;
          -  Completion of informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood donation (500 mL) within the last 8 weeks&#xD;
&#xD;
          -  Fasting blood sugar &gt;100 mg/dL&#xD;
&#xD;
          -  History of coronary artery disease, peripheral vascular disease, or congestive heart&#xD;
             failure&#xD;
&#xD;
          -  Allergy to study drug, components of Boost and Boost Plus, or other study material&#xD;
&#xD;
          -  Clinically significant active or chronic illness&#xD;
&#xD;
          -  History of asthma, COPD, or any other clinically relevant chronic lung disease&#xD;
&#xD;
          -  Respiratory tract infection within 4 weeks before screening&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past 5 years&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
&#xD;
          -  Clinically significant screening ECG, physical examination, laboratory test, or vital&#xD;
             sign abnormality&#xD;
&#xD;
          -  Exposure to any other investigational drug or device within 30 days before treatment&#xD;
             or within 90 days before treatment for drugs known to modify glucose metabolism&#xD;
&#xD;
          -  History of malignancy within the 5 years before screening (other than basal cell&#xD;
             carcinoma)&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection or hepatitis B or C&#xD;
&#xD;
          -  Women who are pregnant, lactating, or planning to become pregnant during the clinical&#xD;
             study period&#xD;
&#xD;
          -  Women of childbearing potential (premenopausal who have not undergone hysterectomy or&#xD;
             bilateral tubal ligation, or postmenopausal for fewer than 2 years) not practicing&#xD;
             adequate birth control. Adequate birth control is defined as using oral, percutaneous,&#xD;
             or transdermal contraceptives; condoms and diaphragms (double barrier) with a&#xD;
             spermicide; or intrauterine devices. Postmenopausal for the purposes of this clinical&#xD;
             study includes experiencing amenorrhea for 2 or more years or being surgically&#xD;
             sterile.&#xD;
&#xD;
          -  Any subject who, in the opinion of the PI or a designee, appears not to be qualified&#xD;
             for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

